Directorio

We are doing this study to better understand women's preferences for and concerns about hormone replacement. We want to learn from women who have had their fallopian tubes and ovaries removed due to BRCA1 and BRCA2 mutations.

We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.

This study has three parts: 1. Getting Ready (Screening) - Takes up to 28 days - You'll get blood tests, a tissue sample, a TB test, and health checkups like scans and heart tests. 2. Treatment (Study Dosing) - People are grouped by race - You'll be randomly picked to get either regular chemo or chemo plus a study medicine (tocilizumab) - Medicine is given every 4 weeks - You'll keep doing health checkups and answer questions. 3. After Treatment (Follow-up) - Happens within 30 days after your last dose - More health checkups and questions to see how you're doing.

We are doing this study to collect breath samples to develop an experimental breath test that aims to detect breast cancer at its earliest stages. Additionally, we will look into whether a person's "breath signature" changes before and after they have undergone surgery for breast cancer.

In this study, people will take a medicine called R289 by mouth once or twice a day. The study has two parts: one part is to find the best dose, and the other part is to test two different doses. You may take the medicine at home or at the clinic. You will visit the clinic regularly for tests like blood work, physical check-ups, and heart exams. Some visits may take up to 8 hours. You can stay in the study as long as the medicine is helping and the side effects are not too strong.

We are doing this study to compare different approaches aimed at preventing strokes for people who have already had a stroke. We want to know what combination of drugs seems to have the best outcomes when it comes to stroke prevention.

We are doing this study to find out if an experimental drug called eplontersen (the study drug) is safe and helpful for people with cardiac amyloidosis. We are enrolling people who previously participated in a clinical trial for this drug called the CardioTTRansform study (ION-682884-CS2).

We are doing this study to find out if an experimental drug called AS 1763 (the study drug) is a safe and effective option patients with B-cell cancers. We also want to know what the maximum, safe dose of the study drug is.